|
Latest
Headlines
| • | Brain tumor survivor is bringing his story to the silver screen (Brattleboro Reformer) | | Wed, 27 Aug 2008 14:58:41 GMT | | • | OR Live and Methodist University Hospital Present: Virtual Brain Tumor Board Webcast Series (Marketwire via Yahoo! Finance) | | Wed, 27 Aug 2008 17:56:00 GMT | | • | Brain tumor survivor is bringing his story to the silver screen (Brattleboro Reformer) | | Wed, 27 Aug 2008 10:03:24 GMT | | • | Fighting a Brain Tumor (KOLN Lincoln) | | Mon, 25 Aug 2008 03:58:44 GMT | | • | Sydney’s story: Inoperable brain tumor more than just statistics (Rockford Register Star) | | Wed, 27 Aug 2008 21:52:05 GMT | | • | Lawsuits Filed In Missouri Brain Tumor Cases (Environment News Service) | | Thu, 28 Aug 2008 03:41:46 GMT | | • | Brain tumor survivors tell their stories (Traverse City Record-Eagle) | | Sun, 24 Aug 2008 14:02:41 GMT | | • | New Approach To Detect Early Progression Of Brain Tumors Identified (Science Daily) | | Thu, 28 Aug 2008 22:21:07 GMT | | • | Barrow researchers identify a new approach to detect the early progression of brain tumors (EurekAlert!) | | Thu, 28 Aug 2008 21:23:46 GMT | | • | Researchers identify a new approach to detect the early progression of brain tumors (PhysOrg) | | Thu, 28 Aug 2008 21:41:12 GMT |
*
Headlines are from industry sponsored news wires, medical journals and
established news organizations from around the world . Please consider the
source of the content when viewing the story.
|
|
UCLA begins new Avastin Trials for Patients with grade IV GBM Tumor
UCLA Neuro-Oncology is sponsoring a Phase II trial which will further
evaluate the safety and effectiveness of Avastin when taken alone or when
taken in combination with Irinotecan a topoisomerase inhibitor. Irinotecan is
also an FDA-approved drug for the treatment of certain other cancers that
directly attacks and damages cancer cells. The study will also determine
whether Avastin with or without Irinotecan can prevent or slow the growth
of the tumor and lead to increase length of survival.
|
|
|
Most
Popular
|
|
